Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States

Apr 18, 2023

NYS Department of Health Clinical Laboratory Evaluation Program certifies Intermountain Precision Genomics Laboratory.

(PRUnderground) April 18th, 2023

Intermountain Precision Genomics and partner Myriad Genetics (NASDAQ: MYGN) are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This achievement follows a recent site inspection as part of the New York State Department of Health Clinical Laboratory Evaluation Program.

“This certification by the New York State Department of Health is a testament to this team’s dedication to laboratory safety and quality. The standard for this certification is high, and we’re proud to deliver on that,” said Jason Gillman, Precision Health Operations director, Intermountain Precision Genomics, a service of Intermountain Health. “Expanding into New York opens the door for Intermountain Precision Genomics and our partners at Myriad Genetics to serve many more patients and healthcare providers than before. We believe our cancer genomics services should be available to every late-stage cancer patient who needs it.”

Intermountain Precision Genomics’ TheraMap®: Solid Tumor genomic test, also offered by Myriad as Precise™ Tumor, analyzes a patient’s tumor DNA to discover what changes, or gene mutations, are causing the cancer. Specialists apply the results to recommend a targeted treatment plan for the patient’s unique tumor profile.

“The NYS certification represents an important step forward in the advancement of precision medicine by increasing access to genetic testing that can help patients with cancer and their providers determine more targeted treatment decisions,” said Michael Lyons, president of Oncology, Myriad Genetics. “Working in close collaboration with Intermountain Precision Genomics, we’re now able to offer the complete Precise Oncology Solutions suite in all 50 states.”

In 2021, Intermountain Health and Myriad announced a collaboration on a comprehensive offering of tests, which includes TheraMap/Precise Tumor. The suite, known as Preciseä Oncology Solutions, provides oncologists with a complete genetic analysis combining somatic tumor profiling, tissue analysis, and germline testing into one report – helping them establish individualized treatment options for each patient.

TheraMap is the first test in Intermountain Precision Genomics history to obtain this certification. Myriad Genetics was previously certified by the New York State Department of Health for its MyRisk® Hereditary Cancer test and somatic tumor profiling MyChoice® CDx test.

Visit IntermountainHealthcare.org/TheraMap for more information about TheraMap testing, or myriad.com/hcp-precise-oncology-solutions for more on Myriad’s Precise Oncology Solutions.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

About Intermountain Health

Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385 clinics, medical groups with some 3,900 employed physicians and advanced care providers, a health plans division called SelectHealth with more than one million members, and other health services. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized as a leader in transforming healthcare by using evidence-based best practices to consistently deliver high-quality outcomes at sustainable costs. For more information or updates, see https://intermountainhealthcare.org/news.

The post Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States first appeared on PRUnderground.

Press Contact

Name: Brad Gillman Phone: 385.275.8245 Email: Contact Us Website: http://intermountainhealth.org

Original Press Release.

More News

Ex-UK PM tells successor to 'move on' from Brexit

Nov 22, 2026

Ex-UK PM tells successor to 'move on' from Brexit

LONDON — Former British prime minister Theresa May said she was "aghast" her successor could be considering rejoining the European Union and urged him to "move on" from Brexit, in comments broadcast Sunday. May's remarks came after Burnham and the EU's top officials on Friday sealed deals at a Brussels summit to ease trade and youth mobility. A decade after Britain narrowly voted to leave the bloc, Burnham has re-energized talk of closer ties ahead of a government 10-year plan for the UK set to be unveiled next month. May warned that negotiations with the EU risked taking up vast amounts of government time, hampering efforts to tackle other issues. "And that's one of the reasons why I look slightly aghast at what Andy Burnham is talking about, further negotiations of going into the EU," she said. May, who supported remaining in the 27-member bloc, said government had to respect the result of the 2016 referendum. "When I became prime minister, I was very clear. People have voted for Brexit. We should deliver Brexit," she told BBC television. "He (Burnham) wants to pat them (voters) on their head and say 'you know what? Remember that vote? Well you got it wrong, didn't you? So have another go and come up with the right answer'," she said. May was forced to quit in May 2019 after failing to get her Brexit deal through parliament. 10-year plan  "My message to him (Burnham) really is: People voted for Brexit. Brexit is done. Just accept Brexit and move on," she added. Burnham, who has been in office since July, has committed to his predecessor Keir Starmer's "red lines" on Europe for this parliament, meaning no return to the single market, customs union or freedom of movement. But pro-Brexit campaigners fear he will push at some point to rejoin the 27-nation grouping. Hamish Falconer, Europe Minister, said the world had changed since 2016 and the UK needed to "think over the long term about our relationship with Europe." "That's why the prime minister is going to set out more next month as part of the 10-year plan about the long-term relationship between the UK and the EU," he told Sky News. But he insisted the British people "are going to be the boss of every stage of this." "We are talking, as the prime minister was clear, about the long term. We will have a general election before then. People will be able to express their views," he said. Following Burnham's EU deals, legislation to allow the UK to align with certain EU rules including on food standards is due to be introduced in parliament this week.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.